I-Mab Biopharma US Limited
I-Mab Biopharma US Limited
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric cancer, gastric neoplasm, metastatic malignant neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-05-14 | NCT07432295 | |
| Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, biliary tract disorder, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric cancer, gastric neoplasm, metastatic malignant neoplasm, neoplasm, stomach disorder | Recruiting | Phase 1 | 2026-03-05 | NCT04900818 |